メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
藤田医科大学でコンテンツを検索
ホーム
プロファイル
研究部門
研究成果
Scopus著者プロファイル
大矢 由子
医学部・呼吸器内科学
h-index
1394
被引用数
22
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2015
2026
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(66)
類似のプロファイル
(6)
フィンガープリント
Yuko Oyaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
5%
Adverse Event
17%
Alectinib
5%
Anaplastic Lymphoma Kinase
20%
Anaplastic Thyroid Carcinoma
5%
Biological Marker
7%
Bronchopleural Fistula
5%
Cardiotoxicity
5%
Ceritinib
5%
Chemoradiation Therapy
10%
Chemotherapy
28%
Cohort Study
28%
Combination Therapy
12%
Crizotinib
15%
Dabrafenib
5%
Disease
6%
Durvalumab
5%
Epidermal Growth Factor Receptor
58%
Eribulin
5%
Erlotinib
6%
Fenbendazole
5%
Immune Checkpoint Inhibitor
25%
Immunotherapy
5%
Indocyanine Green
5%
Lung Cancer
48%
Malignant Neoplasm
8%
Malignant Pleura Effusion
5%
Monotherapy
8%
Neoplasm
9%
Nivolumab
11%
Non Small Cell Lung Cancer
91%
Osimertinib
29%
Overall Survival
16%
Pembrolizumab
13%
Pneumonia
21%
Postoperative Complication
5%
Programmed Cell Death
11%
Programmed Death 1 Ligand 1
11%
Progression Free Survival
27%
Protein Mcl 1
5%
Protein Tyrosine Kinase Inhibitor
11%
Quantum Dot
5%
Ramucirumab
5%
Retrospective Study
15%
Small Cell Lung Cancer
10%
Squamous Cell Carcinoma
5%
Thyroid Cancer
5%
Thyroid Papillary Carcinoma
9%
Trametinib
5%
Xenon
5%
Medicine and Dentistry
Adverse Event
11%
Bronchopleural Fistula
5%
Carcinoma
5%
Chemoradiotherapy
19%
Chest Tube
5%
Clinical Stage
5%
Cohort Analysis
6%
Computer Assisted Tomography
5%
Diagnosis
5%
Disease
6%
Disease Free Survival
13%
Durvalumab
20%
EGFR Inhibitors
5%
Epidermal Growth Factor Receptor
28%
Erlotinib
5%
Gene Mutation
6%
Hazard Ratio
9%
Immune Checkpoint Inhibitor
18%
Immune-Related Adverse Events
5%
Immunotherapy
10%
Intensity Modulated Radiation Therapy
10%
Lobectomy
17%
Long Term Survival
5%
Lung
10%
Lung Adenocarcinoma
10%
Lung Cancer
36%
Lung Function
5%
Lymph Node
5%
Lymph Node Metastasis
5%
Malignant Pleural Effusion
5%
Mediastinal Germ Cell Tumor
5%
Neoplasm
10%
Non Small Cell Lung Cancer
100%
Non-Small Cell Lung Cancer
16%
Oncogene
6%
Osimertinib
18%
Overall Survival
17%
Pembrolizumab
17%
Pneumonia
31%
Positron Emission Tomography-Computed Tomography
6%
Programmed Cell Death
5%
Programmed Death 1 Ligand 1
10%
Progression Free Survival
18%
Radiofrequency Ablation
5%
Recurrent Disease
6%
Retrospective Cohort Study
17%
Retrospective Study
14%
Segmentectomy
6%
Surgery
9%
Xenon
5%
Keyphrases
Adverse Events
5%
ALK Rearrangement
5%
Anaplastic Lymphoma Kinase Fusion
5%
Ceritinib
5%
Chemotherapy
6%
Clinical Outcomes
11%
Combination Therapy
6%
Concurrent Chemotherapy
5%
Confidence Interval
10%
Corticosteroids
5%
Crimson
5%
EGFR mutation
16%
EGFR T790M
5%
Elderly Patients
10%
Elderly People
5%
Epidermal Growth Factor Receptor
15%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
7%
Fluorimetry
5%
Fusion Variants
5%
Genomic Test
5%
Guideline Methodology
5%
Hazard Ratio
8%
High Risk Histology
5%
Immune Checkpoint Inhibitor Therapy
6%
Immune Checkpoint Inhibitors
9%
Immune-related Adverse Events
5%
Intensity-modulated Radiation Therapy
5%
IrAE
5%
Lung Cancer
6%
Multicenter Retrospective Study
5%
Nanodrop
5%
Non-elderly
10%
Non-small Cell Lung Cancer (NSCLC)
38%
Non-small Cell Lung Cancer Patients
5%
Osimertinib
17%
Overall Survival
12%
PD-1 Inhibitor
5%
Pneumonitis
10%
Propensity Score Analysis
5%
Qubit
5%
Real-world Survey
5%
Retrospective Analysis
5%
Risk Factors
6%
ROS1 Rearrangement
5%
Small Cell Lung Cancer Transformation
5%
Spectrophotometry
5%
Stage IV NSCLC
5%
Sublobar Resection
5%
T790M mutation
6%
Total Lesion Glycolysis
5%
